Indegene welcomes Jill DeSimone, a life sciences leader, and Neeraj Bharadwaj, a private equity executive, to its Board of Directors. These appointments aim to enhance Board oversight, strengthen governance, and leverage technology-led life sciences modernization. Both new members bring extensive experience and are expected to contribute significantly to Indegene’s strategic direction and value creation.
Board Strengthened with Key Appointments
Indegene has announced the addition of Jill DeSimone and Neeraj Bharadwaj to its Board of Directors, effective January 29, 2026. These appointments are expected to bolster the company’s strategic oversight and governance capabilities.
Experience of New Board Members
Jill DeSimone brings over four decades of life sciences leadership experience. She has held leadership positions at major biopharma companies, including Merck where she led the launch of Keytruda. She also held leadership roles at Teva and Bristol Myers Squibb.
Neeraj Bharadwaj has extensive experience in private equity and capital allocation. He is currently a Senior Advisor with Carlyle Asia and has previously held leadership roles at Accel Partners and Apax Partners.
Strategic Impact
The addition of DeSimone and Bharadwaj is expected to support Indegene’s long-term growth, corporate governance, and technology-driven innovation in the life sciences sector. Their expertise is intended to strengthen the company’s strategic direction and enhance value for stakeholders.
Statements from New Board Members
Jill DeSimone stated she is eager to partner with the leadership team to help strengthen the company’s impact across the commercialization value chain.
Neeraj Bharadwaj looks forward to supporting the company’s sustained growth and disciplined value creation.
Source: BSE
